AI Spotlight on DESN
Company Description
Dottikon Es Holding AG engages in the manufacture and sale of performance chemicals, intermediates, and active pharmaceutical ingredients for the chemical, biotech, and pharmaceutical industries worldwide.The company's chemicals and intermediates include amines, anilines, azaindoles, benzimidazoles, benzoic acid derivatives, benzyl compounds, boron building blocks, chiral compounds, cyclohexane derivatives, cyclopropyl building blocks, indazoles, indoles, N-heterocycles, nitrate esters, nitroaromatic compounds, O-heterocycles, phenols and anisoles, and pyridine building blocks.It also provides Dottisol, an isosorbide dimethyl ether for application as a solubility enhancer in cosmetic, pharma, and agro products, as well as a performance additive in various industries.
In addition, the company is involved in recycling, thermal recovery, and high-temperature incineration of waste streams, as well as wastewater treatment and purification activities; and provision of consulting services for investment companies, and software and engineering services.Dottikon Es Holding AG was founded in 1913 and is headquartered in Dottikon, Switzerland.Dottikon Es Holding AG is a subsidiary of EVOLMA Holding AG.
Market Data
Last Price | 219 |
Change Percentage | -0.68% |
Open | 221 |
Previous Close | 220.5 |
Market Cap ( Millions) | 3026 |
Volume | 2620 |
Year High | 270 |
Year Low | 206 |
M A 50 | 224.51 |
M A 200 | 244.6 |
Financial Ratios
FCF Yield | -1.93% |
Dividend Yield | 0.00% |
ROE | 9.34% |
Debt / Equity | 11.29% |
Net Debt / EBIDTA | -70.72% |
Price To Book | 3.42 |
Price Earnings Ratio | 37.53 |
Price To FCF | -51.84 |
Price To sales | 9.27 |
EV / EBITDA | 25.84 |
News
Business Breakdown
Expected Mid-Term Growth
Segment nΒ°1 -> Chemicals, Intermediates, and Exclusive Active Pharmaceutical Ingredients
Expected Growth : 10 %
What the company do ?
Dottikon Es Holding AG offers Chemicals (building blocks for APIs), Intermediates (partially synthesized APIs), and Exclusive Active Pharmaceutical Ingredients (high-purity APIs) for pharmaceutical manufacturing.
Why we expect these perspectives ?
Dottikon Es Holding AG's 10% growth in Chemicals, Intermediates, and Exclusive Active Pharmaceutical Ingredients is driven by increasing demand for specialty chemicals, growing pharmaceutical industry, and rising need for high-purity ingredients. Additionally, strategic partnerships, capacity expansions, and investments in R&D are contributing to the company's growth momentum.
Dottikon Es Holding Ag Products
Product Range | What is it ? |
---|---|
Pharmaceutical Intermediates | Dottikon Es Holding AG offers a range of pharmaceutical intermediates, which are used as raw materials in the production of active pharmaceutical ingredients (APIs). |
Agrochemical Intermediates | The company provides agrochemical intermediates, which are used in the production of pesticides, herbicides, and other crop protection products. |
Fine Chemicals | Dottikon Es Holding AG offers a range of fine chemicals, including specialty chemicals and performance chemicals. |
Custom Manufacturing | The company provides custom manufacturing services for pharmaceutical, agrochemical, and fine chemical products. |
Contract Research and Development | Dottikon Es Holding AG offers contract research and development services for pharmaceutical, agrochemical, and fine chemical products. |
Dottikon Es Holding AG's Porter Forces
Threat Of Substitutes
The threat of substitutes for Dottikon Es Holding AG is moderate, as there are some alternatives available in the market, but they are not very attractive to customers.
Bargaining Power Of Customers
The bargaining power of customers for Dottikon Es Holding AG is low, as customers have limited options and the company has a strong brand presence.
Bargaining Power Of Suppliers
The bargaining power of suppliers for Dottikon Es Holding AG is moderate, as the company has some dependence on its suppliers, but it also has some bargaining power due to its size and reputation.
Threat Of New Entrants
The threat of new entrants for Dottikon Es Holding AG is high, as the industry is attractive and there are low barriers to entry.
Intensity Of Rivalry
The intensity of rivalry for Dottikon Es Holding AG is high, as the industry is highly competitive and there are many players competing for market share.
Capital Structure
Value | |
---|---|
Debt Weight | 6.95% |
Debt Cost | 3.95% |
Equity Weight | 93.05% |
Equity Cost | 9.00% |
WACC | 8.65% |
Leverage | 7.47% |
Dottikon Es Holding AG : Quality Control
Dottikon Es Holding AG passed 5 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
Company | Rational |
---|---|
BANB.SW | Bachem Holding AG provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide β¦ |
MNDI.L | Mondi plc engages in the manufacture and sale of packaging and paper products in Africa, Western Europe, Emerging Europe, Russia, North America, South America, Asia, and Australia. It operates in β¦ |
KEMIRA.HE | Kemira Oyj operates as a chemicals company in Finland, rest of Europe, the Middle East, Africa, the Americas, and the Asia Pacific. It operates in two segments, Pulp & Paper β¦ |
SOLB.BR | Solvay SA provides advanced materials and specialty chemicals worldwide. It operates through four segments: Materials, Chemicals, Solutions, and Corporate & Business Services. The Materials segment offers specialty polymers, including aromatic β¦ |
SOL.MI | SOL S.p.A. engages in the applied research, production, and marketing of technical and medical gases; and in home medical assistance and related medical equipment in Italy and internationally. The company β¦ |